Editas Medicine, Inc.

Contributing Author

Recent Articles by Editas Medicine, Inc.

Jun-12	Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June EDIT GlobeNewswire
May-14	Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June EDIT GlobeNewswire
May-14	Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting EDIT GlobeNewswire
May-13	Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting EDIT GlobeNewswire
May-12	Editas Medicine Announces First Quarter 2025 Results and Business Updates EDIT GlobeNewswire
May-12	Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board EDIT GlobeNewswire
May-05	Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May EDIT GlobeNewswire